115 reports of this reaction
1.7% of all DESVENLAFAXINE reports
#14 most reported adverse reaction
SEROTONIN SYNDROME is the #14 most commonly reported adverse reaction for DESVENLAFAXINE, manufactured by Actavis Pharma, Inc.. There are 115 FDA adverse event reports linking DESVENLAFAXINE to SEROTONIN SYNDROME. This represents approximately 1.7% of all 6,688 adverse event reports for this drug.
Patients taking DESVENLAFAXINE who experience serotonin syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEROTONIN SYNDROME is a less commonly reported adverse event for DESVENLAFAXINE, but still significant enough to appear in the safety profile.
In addition to serotonin syndrome, the following adverse reactions have been reported for DESVENLAFAXINE:
The following drugs have also been linked to serotonin syndrome in FDA adverse event reports:
SEROTONIN SYNDROME has been reported as an adverse event in 115 FDA reports for DESVENLAFAXINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEROTONIN SYNDROME accounts for approximately 1.7% of all adverse event reports for DESVENLAFAXINE, making it a notable side effect.
If you experience serotonin syndrome while taking DESVENLAFAXINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.